Feasibility of Human Immunodeficiency Virus Vaccine Trials in Homosexual Men in the United States: Risk Behavior, Seroincidence, and Willingness to Participate
Human immunodeficiency virus (HIV)-seronegative high-risk homosexual men were enrolled in a vaccine feasibility study in three US cities. HIV seroincidence was 2.31100 person-years (95% confidence interval [CI], 1.7-2.9) over 18 months in 1975 men. After receiving an explanation of HIV vaccine trial design, 37% stated they were "definitely" willing to participate in future trials; seroincidence was 3.71100 person-years (95% CI, 2.5-4.9) in this subgroup. An additional 57% "might be" or were "probably" willing.Independent predictors of HIV seroconversion in multivariable pooled logistic regression analysis were having a known HIV-seropositive sex partner (odds ratio [OR], 4.5; 95% CI, 2.6-7.8), injection drug use (OR, 3.6; 95% CI, 1.2-10.7), unprotected receptive anal sex (OR, 2.4; 95% CI, 1.4-4.2), condomfailure (OR, 2.4;95%CI, 1.4-4.1), gonococcal! nongonococcal urethritis (OR, 2.3; 95% CI, 1.1-4.7), and age <25 years (OR, 2.2; 95% CI, 1.2-4.2). Interest in vaccine trials and seroincidence in high-risk homosexual men are sufficiently high to initiate efficacy trials once a suitable candidate vaccineis identified.Risk factors for seroconversion highlight important areas for development of ancillary intervention strategies.
Behavioral change is the only known effective approach to decrease the risk of human immunodeficiency virus (HIV) transmission. Although great strides have been made among communities of homosexual men in instituting safer sex practices [1, 2] , persons continue to become HIV-infected through unsafe sexual behavior and needle sharing. About 40,000 adolescents and adults in the United States become HIV-infected annually [3] , with 2.1 million infections occurring worldwide [4] . Development of an effective vaccine for the prevention of HIV transmission could significantly reduce the continuing spread of the epidemic in the United States and around the world.
In evaluating the feasibility of conducting future preventive HIV vaccine efficacy trials in the United States, several ques-tions must be addressed. Projections must be made about the degree to which high-risk persons will enroll in placebo-controlled efficacy trials. Determination of sample size for such trials will depend on accurate estimates of HIV seroincidence in high-risk persons most likely to enroll in trials. However, seroincidences may not be uniform throughout a vaccine trial period because of early seroconversion and selective loss to follow-up of those at highest nsk as well as decreases in li~k. behavior in those retained in the trial [5] . Estimates of seroincidence after the initial 6 months of a study are particularly important because vaccines may not induce immune responses until several injections have been administered [6] . In addition, initial vaccine candidates are unlikely to be 100% effective at preventing HIV infection. Development of behavioral prevention strategies to supplement vaccines requires an understanding of current risk factors for HIV seroconversion in these populations.
To prepare for vaccine efficacy trials, the National Institute of Allergy and Infectious Diseases, the Centers for Disease Control and Prevention (CDC), and the National Institute on Drug Abuse collaboratively sponsored HIV seroincidence and vaccine feasibility studies in the United States. These"Jumpstart" studies were a precursor to the current HIV Network for Prevention Trials currently underway [7] . We report on 18 months of follow-up from the Jumpstart study ofHIV-seronegative homosexual men conducted in three US cities.
Methods
Health Department, and the San Francisco AIDS Office used uniform study protocols to enroll and follow HIV-seronegative homosexual men. We report on data collected through 31 March 1995.
To be enrolled, men~18 years of age were required to be HIVseronegative and to report at least one episode of high-risk sexual activity with a man in the 12 months before study entry. Highrisk activity was initially defined as unprotected insertive or receptive anal sex or a diagnosis of syphilis, gonorrhea, or nongonococcal urethritis. Two months after the study began, the enrollment criteria were expanded to include men reporting protected anal sex in the prior 12 months. These broader criteria enabled us to include men underreporting unprotected anal sex on a brief screening questionnaire and men with episodic risky behavior. Because there have been several case reports of seroconversion occurring from receptive orogenital sex in San Francisco [8, 9] , the San Francisco site also included men reporting unprotected receptive orogenital sex with ejaculation as a high-risk activity. Each study site planned to rapidly enroll 500 eligible men and then continue a slower rate of participant accrual to replace participants who might seroconvert or drop out of the study.
Sites used a variety of recruitment techniques to target highrisk men. Strategies included enrollment from sexually transmitted disease (STD) clinics and HIV testing sites, advertising, outreach at street comers and dance clubs, referrals by enrolled participants (snowball sampling), and referrals from other studies. Men were screened for eligibility using a brief confidential questionnaire, and those appearing to be eligible were offered HIV antibody counseling and testing. Specimens repeatedly reactive by EIA were confirmed by Western blot techniques or immunofluorescence assay, and participants with confirmed positive results were counseled but not enrolled in the study. Men who were HIV-seronegative at baseline received an extensive behavioral interview. Participants returned every 6 months for HIV antibody testing, counseling, and behavioral interviews. Participants returned 2 weeks after each of these visits to be counseled about their HIV antibody test results. Participants who seroconverted during the study were referred for care but were no longer followed.
Behavioral questionnaires included both interviewer-administered and self-administered questions on sexual and drug use practices, STDs, and psychosocial parameters. Questions did not differentiate between urethral gonorrhea and nongonococcal urethritis because of the difficulty of obtaining reliable self-reported data for individual diagnoses. After a brief description of trial design, including placebo controls, randomization, blinding, and the possibility of vaccine-induced false-positive HIV antibody tests, participants' willingness to participate in a preventive HIV vaccine trial was assessed using a 4-point Likert scale ranging from "definitely" to "not at all" willing to participate.
Statistics. Retention rates at 6, 12, and 18 months were estimated by the method of Kaplan-Meier; pooled logistic regression was used to determine independent predictors of loss to followup. HIV-l seroincidence per person-year, together with~95% Poisson confidence intervals (CI), was calculated overall and for 6-month intervals and stratified by baseline willingness to participate in HIV vaccine trials. Baseline demographics, as well as potential risk factors for seroconversion, were compared across sites using X 2 and Wilcoxon tests. Information on risk behavior from different visits was summarized by averaging measures of exposure evaluated at each follow-up visit over the previous 12 months. The l2-month retrospective time period was chosen because a seroconversion detected at a given visit could have resulted from exposures in either of the two previous 6-month intervals.
To identify predictors of HIV seroconversion, we first estimated univariate associations of seroconversion with demographics, sexual behaviors, drug use practices, and STDs. In a preliminary univariate analysis, we evaluated retrospective measures of exposure for seroconverters over the 12-month period preceding their first positive visit, while for controls we used the summary exposure measures just described. Scores on each such measure were compared using the t test. Pooled logistic regression, using timedependent exposure measures [10] , was used to identify independent predictors of seroconversion. Model selection was carried out using a forward stepwise procedure, beginning with the set of significant (P < .1) univariate predictors. All models included indicators for visit and city of recruitment.
The mean person-specific rate of condom failure was estimated by averaging the ratio of the number of episodes in which each participant reported that condoms broke or slipped off to the estimated number of times he used condoms for anal sex. The overall per-condom failure rate was estimated by the ratio of the total number of episodes of slippage or breakage reported by all participants to the corresponding total number of condoms used. Univariate predictors of reporting any condom failure were evaluated using the X 2 or Wilcoxon tests. To evaluate the proportion of seroincidence attributable to each ofthe independent risk factors for HIV seroconversion, attributable fraction was calculated as the ratio of the average excess risk to average risk, where both were estimated from the logistic model.
Last, we evaluated changes in reported risk for men seen at all follow-up visits. Behavior change was assessed from baseline to l8-month follow-up by Cochran's Q test for categorical variables and Friedman's test for the number of sex partners.
Results
From January 1993 through July 1994, 2189 men were enrolled in the study, with the first 1500 (original target number) recruited within 7 months. After accounting for censoring, estimated retention at 6, 12, and 18 months was 90%, 84%, and 78%, respectively. Independent baseline predictors of loss to follow-up included age <25 years (odds ratio [OR], 1.7; 95% CI, 1.4-2.2), having moved more than twice in the last 2 years (OR, 1.6; 95% CI, 1.3-2.0), and use of cocaine (OR, 1.6; 95% CI, 1.3 -2.1). In addition, nonwhite racelethnicity (OR, 1.6; 95% CI, 1.2-2.2), lack of health insurance (OR, 2.1; 95% CI, 1.6-2.9), and injection drug use (OR, 2.2; 95% CI, 1.0-4.6) predicted loss to follow-up in the interval between baseline and 6-month follow-up, while "popper" (amyl nitrite) use was associated with increased retention during this period (OR, 0.6; 95% CI, 0.4-0.9). Loss rates declined significantly after the 6-month visit, from 10% to~7% in the two remaining intervals, but after controlling for other risk variables did not differ by site. There was also a trend toward lower retention among men who were' 'not at all" willing to participate in a preventive HIV vaccine trial (OR, 1.4; 95% CI, 1.0-2.0). In univariate models controlling for site and visit, unprotected receptive anal intercourse, report of condom breakage, and marijuana and amphetamine use were the sexual and drug use variables also associated with loss to follow-up. The remainder of this analysis is restricted to the 1975 men with at least one follow-up HIV test. There were significant differences in the demographic characteristics and prevalence of risk behaviors between the three cohorts, reflecting differences in recruitment strategies and populations at the three sites (table 1) . Men in all three cohorts were relatively young, with a median age of 31. The racial makeup of the cohorts significantly differed by city. Men recruited in Denver and San Francisco were significantly more likely to have a low annual income and lack health insurance than men recruited in Chicago. Men from San Francisco were more likely to report a greater number of sex partners, at least one known HIV-positive sex partner, condom failure, and urethritis than men from either of the other sites. Drug use patterns differed in the three cities, tending to be highest in San Francisco.
There were a total of 59 HIV seroconversions across the three sites, representing an annualized seroincidence of 2.3/ 100 person-years (95% CI, 1.7-2.9) (table 2). Although there were site differences in these point estimates, pooled logistic regression models gave no evidence for significant differences in risk of seroconversion by site. Likewise, there was no statistically significant change in seroincidence over the first 18 months of the study.
After hearing a brief explanation of randomized clinical trial design, 37% of the men stated at baseline that they were "definitely" willing to participate in a preventive HIV vaccine trial, and an additional 57% said that they "might be" or were "probably" willing. Among men stating they were "definitely" willing to participate, HIV seroincidence was 3.7/100 person-years (95% CI, 2.5-4.9) (table 2). Of the 59 seroconverters, 34 (58%) had stated at baseline that they would be "definitely" willing to participate in a preventive HIV vaccine trial. Next, we compared the demographic characteristics and risk behaviors reported by seroconverters with those reported by nonconverters. Seroconverters were significantly younger, had lower incomes, and were more likely to be medically uninsured than nonconverters (table 3) . There were no significant differences in other demographic variables between seroconverters and nonconverters. Seroconverters were significantly more likely than nonconverters to have reported any of several sexual risk factors, including a greater number of sex partners per 6-month interval, sex with a known HIV-positive partner, unprotected receptive anal sex, and condom failure (breakage or slippage). Seroconverters were also significantly more likely to report urethritis and genital warts than nonconverters but no more likely to report rectal gonorrhea, syphilis, or episodes of genital herpes.
Condom breakage or slippage was commonly reported by the cohort, with 38% of the men who used condoms reporting at least one episode of condom failure during follow-up. Most men reported only one episode of condom failure, although 36% of the men reporting condom failure experienced more than two episodes in any 6-month period (range, 1-20). The average per-person condom failure rate for anal sex was 4.5 per 100 episodes of condom use, while the overall per-condom rate was 1.8. Among men using condoms, those who reported condom failure were significantly more likely to be <25 years (21% vs. 14%, P = .001); be nonwhite (25% vs. 20%, P = .01); have an annual income under $20,000 (45% vs. 39%, P = .006); be recruited from an STD clinic (31% vs. 25%, P = .004); use cocaine (14% vs. 11%, P < .001), amphetamines (16% vs. 10%, P < .001), hallucinogens (11% vs. 6%, P < .001), barbiturates (3% vs. 2%, P < .002), or poppers (28% vs. 22%, P = .001); and have a larger number of sex partners (median, 4.7 vs. 3.0 per 6-month period, P < .001).
Only 2.5% of the cohort reported injecting drugs in the prior 12-month period, but the risk of seroconversion was somewhat higher in these men than in men who did not report injecting drugs (table 3) . Seroconverters were more likely to report a history of cocaine, amphetamine, popper, hallucinogen, or marijuana use than nonconverters. Seroconverters were also more likely than nonconverters to have used alcohol just before sexual activity. Because of differences in the demographic and risk behavior profiles of the cohorts from the three sites and because HIV seroprevalence and thus the possibility of exposure may differ by city, we controlled for city in the multivariable model. We also included age and race as covariates in the model. The independent predictors of HIV seroconversion and their attributable risks are shown in table 4. Seroconversion was also significantly more likely to occur in participants who stated they were "definitely willing" to participate in future HIV vaccine trials (OR, 2.1; 95% CI, 1.3-3.7) and in participants who were medically uninsured (OR, 2.7; 95% CI, 1.6-4.8). However, these variables were excluded from the final model, which focused on potential causal factors. Variables that were eligible for entry into the model but that were not independently associated with seroconversion included race; number of sex lucinogen, marijuana, and alcohol use. All of the seroconverters reported having had anal sex in the 12 months before their first HIV positive test, although 10% reported having insertive but not receptive anal sex. In addition, 12% of the seroconverters had reported that they had only engaged in protected anal sex without condom failure.
To evaluate the usefulness of different eligibility criteria, we estimated the increase in the HIV seroincidence rate that would result from recruiting only men who report unprotected anal sex on screening. HIV seroincidence in men reporting unprotected anal sex on screening was 2.8/100 person-years (95% CI, 1.9-3.7), and this subsample accounted for 51% of the cohort. However, 40% of the seroconverters would not have been enrolled using these more restrictive criteria, and loss to follow-up among the subsample meeting the more restrictive criteria was significantly elevated compared with the rest of the cohort (OR, 1.3; 95% CI, 1.0-1.6).
Last, we evaluated change in risk behavior over time in men retained in the cohort through 18 months of follow-up. There was a small but statistically significant decrease in most of the sexual risk factors and drug use practices associated with HIV seroconversion on univariate analysis (table 5) . In most instances, risk reduction occurred early in the study, with significant decreases in reported risk between baseline and 6-month interviews and a leveling off after 6 months.
Discussion
Our results indicate that preventive HIV vaccine trials in the United States will be feasible once a suitable candidate vaccine is identified. Within a 7-month period, we recruited a young, ethnically diverse cohort of> 1500 HIV-uninfected homosexual men in three cities. HIV seroincidence in this cohort remained >2/100 person-years over 18 months of follow-up, and initial interest in vaccine trials was high. Cohorts of injection drug users have produced similar seroincidence rates [11, 12] , and interest in vaccine trials may also be high in these populations [13, 14] . With an annualized seroincidence of 21100 person-years, ,...., 5000 participants would be required for a placebocontrolled vaccine trial to detect with 90% power a vaccine of 50% efficacy [15] .
Our study provides important lessons for future vaccine trials. After receiving an explanation of randomized clinical trial design and the possibility of vaccine-induced false-positive HIV antibody tests, 37% of the cohort said that they were "definitely" willing to participate in preventive HIV vaccine trials and only 6% said that were unwilling to participate. Seroincidence was highest among those who were "definitely" willing to participate. This is consistent with the findings of a cross-sectional survey of injection drug users that found an association between high-risk drug-using behavior and willingness to participate in HIV vaccine trials [13] . An earlier analysis from our study found that 37% of the men "definitely" willing to l'~rtic'irate in vaccine trials stated that one motivation would be a reduction in the risk of becoming HIV-infected [16] , and similar findings were reported in injection drug users [13] . These results highlight the importance of educating potential participants and their communities that vaccine trials will test vaccines of unknown and unproved efficacy and use a placebo as a control. Counseling and other behavioral interventions should be included in vaccine trials to minimize the likelihood that participants will increase their risk during the trial.
In recruiting persons for vaccine efficacy trials, eligibility criteria must be designed to balance seroincidence against the ease and cost of recruitment and retention. If we had restricted enrollment to men with unprotected anal sex, seroincidence would have been slightly higher, but we would have recruited only 51% of the current cohort and only 60% of the men who ultimately became HIV-infected. Moreover, we would have had a greater problem with retention. In addition, some participants appear to underreport risk on screening that they later report at in-depth interviews [17, 18] . Thus, the looser criteria eventually used in Jumpstart seem to strike a better balance than the earlier, more restrictive ones.
HIV seroincidence may decrease in longitudinal studies because of early seroconversions in men at highest risk, selective loss to follow-up, and decreases in risk activity in men re- maining in the study. Despite decreases in reported risk activity, we did not detect a significant decrease in seroincidence over this I8-month study. One possible explanation for this discrepancy is that the decline in risk was of insufficient magnitude to affect the rate of seroconversion. It is also possible that because of social desirability, participants increasingly underreported risk as they developed relationships with study staff. New studies will evaluate alternative techniques for measuring risk, including self-administered and computer-administered questionnaires.
Our study also provides information on predictors of seroconversion among homosexual men that may be useful for shaping prevention strategies. Having a known HIV-positive sex partner was most strongly associated with HIV seroconversion, highlighting the importance of HIV seropositivity in the partner pool in determining HIV seroconversion rates. Consistent with prior studies [9, [19] [20] [21] [22] [23] , unprotected receptive anal sex was an independent predictor of HIV seroconversion and had the second highest attributable risk. Condom failure also appeared to account for a substantial proportion of seroconversions. The rate of condom failure in this study was within the range for breakage and/or slippage in men reported in the literature (2.7%-4.9% per person and 1.9%-8.0% per condom) [24] [25] [26] [27] [28] [29] [30] and is also supported by laboratory-based tests [31, 32] . Condom failure rates may also be somewhat higher in anal sex than vaginal sex [24, 26] . Higher rates of condom failure in young men and those who use drugs suggests that some condom failure may be the result of improper usage due to lack of experience, prolonged sexual intercourse, or impaired abilities.
Urethritis was also significantly associated with HIV seroconversion. Although ulcerative STDs, including herpes and syphilis, were not associated with seroconversion, we may have underestimated these risks because we used self-reports only. While the association of urethritis with HIV seroconversion may merely represent two different biologic outcomes of highrisk sexual behavior, it is also possible that nonulcerative STDs of the genital tract may playa direct role in HIV transmission among homosexual men, as has been suggested for heterosexuals [33, 34] .
This study extends the findings of cross-sectional surveys that suggest that young homosexual men engage in riskier sexual activity than older homosexual men [35] [36] [37] . We found that being <25 years of age was a significant independent predictor of HIV seroconversion. Although young men were significantly more likely to report high-risk sexual activity, they were significantly less likely to report having a known HIV-positive partner. The latter difference may reflect a lower seroprevalence in the partner pool of young men or a decreased awareness of partner HIV serostatus. The median age of seroconverters was 29, indicating that a significant number of new infections occur in "older" homosexual men.
The independent association of injection drug use with HIV seroconversion in this study suggests that for a minority of men in our cohort, HIV may have been transmitted parenterally. Noninjection drug use was also significantly associated with seroconversion on univariate analysis, presumably through an association of drug use with other high-risk sex practices. Other studies have demonstrated an association between noninjection drug use and HIV seroprevalence or high risk sex practices [38] [39] [40] [41] [42] .
Finally, young men, men with risky sex practices, and drug users were significantly more difficult to retain but also were more likely to seroconvert. Strategies must be developed to enhance retention of these subgroups. Many men failing to return for this study had moved away from the study site, suggesting that arranging travel for participants may enhance retention.
OUf data indicate that domestic vaccine trials are feasible among homosexual men, although much preparation remains to be done. We must educate individuals and communities about vaccines and nonvaccine interventions. Participants must be fully informed of the potential risks and benefits of participation. Strategies must be developed to ensure high retention rates throughout a vaccine trial. Seroincidence should be measured over several years to ensure that any significant long-term decline in seroincidence is accounted for in sample size calculations. Ongoing counseling must focus on factors associated with seroconversion, and the impact of these efforts on HIV seroincidence must be measured. Last, such studies should identify persons who have been exposed to HIV yet remain uninfected. Exploration of possible immunologic or genetic mechanisms for protection from HIV infection could lead to insights in the development of successful preventive vaccines.
